FDA approved Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer January 4, 2023
Lynparza + abiraterone approved in the EU in 1L metastatic CRPC based on Ph 3 PROpel trial results January 4, 2023
Calquence approved in Japan for adults with treatment-naïve chronic lymphocytic leukaemia January 4, 2023
Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for unresectable biliary tract and liver cancers January 4, 2023
Enhertu approved in the EU for patients with previously treated HER2-positive advanced gastric cancer January 4, 2023
